Introduction
============

Delirium is a common and serious condition in older hospitalized patients. The prevalence in hospitalized elderly patients is as high as 50%, being present in 11%--24% of older patients at admission, with another 5%--35% developing delirium during admission.[@b1-cia-8-565],[@b2-cia-8-565] It is an indicator of severe underlying illness, necessitating early diagnosis and prompt treatment. Despite varying etiologies, delirium has a characteristic constellation of symptoms, suggesting a common neural pathway. Importantly, motor symptoms are core symptoms, associated with cognitive impairments and sleep disturbances.

The usually cited factors for delirium include advanced age, preexisting cognitive impairment, serious medical conditions, medications (such as benzodiazepines), environmental factors, and sleep deprivation. Attention and memory impairment have been observed after periods of total and partial sleep deprivation,[@b3-cia-8-565],[@b4-cia-8-565] suggesting a mechanistic relationship between delirium and sleep deprivation that may be mediated through involvement of the cholinergic and dopaminergic systems, although direct relationship between the two remains to be fully elucidated. Most of the available literature on delirium and sleep have involved intensive care unit patients. Critically ill patients, especially older adults, are known to experience poor sleep quality, with severe sleep fragmentation and sleep architecture disruption.[@b5-cia-8-565],[@b6-cia-8-565]

Delirium is associated with an increased need for nursing surveillance, greater hospital costs, and high mortality rates of 25%--33% during hospitalization and 35%--40% at 1 year.[@b7-cia-8-565]--[@b12-cia-8-565] In partial response to this, the Geriatric Monitoring Unit (GMU) was developed in October 2010 at the Tan Tock Seng Hospital, Singapore, using an evidence-based approach incorporating specific interventions established to be beneficial for delirium care. The details of the GMU have been published previously.[@b13-cia-8-565] To summarize, the GMU incorporated specific measures from the following programs: (1) Delirium Room, which provides comprehensive medical care, with multidisciplinary team meetings, and employs behavioral and appropriate nonpharmacological strategies as first-line management in delirious patients,[@b14-cia-8-565] (2) the concept of structured core interventions from the Hospital Elder Life Program (HELP),[@b15-cia-8-565]--[@b22-cia-8-565] and (3) bright light therapy to establish a healthy sleep--wake cycle, with appropriate timing to effectively shift an altered circadian sleep--wake cycle to the desired phase.

Bright light therapy has gained increasing attention in recent years, as a potential environmental modifier (zeitgeber) of circadian rhythms. Additionally, therapeutic benefits have been demonstrated in terminally ill patients,[@b23-cia-8-565] as well as those with seasonal affective disorders.[@b24-cia-8-565] In elderly patients with advanced sleep phase syndrome, evening exposure to bright light daily has been demonstrated to be beneficial.[@b25-cia-8-565]--[@b31-cia-8-565] This can be achieved using a bright light box of 1000--3000 lux or natural exposure to the sun for 1--2 hours daily in the late afternoon and early evening. The aim of bright light therapy is to establish healthy sleep--wake cycles. A recent study demonstrated the utility of light therapy in adjusting the rest--activity cycle and improving bed rest in postesophagectomy patients, with decreased occurrences of incident delirium.[@b32-cia-8-565] Since sleep deprivation may aggravate delirium, it was anticipated that delirious patients would benefit from modulation of their sleep--wake cycle, while in the GMU. The peaceful environment of the GMU (without potential disruption by other patients) would facilitate uninterrupted sleep at night, while structured core interventions (with therapeutic activities) aimed to keep patients engaged in the day.

This study examined the impact of the GMU as a multicomponent intervention on outcomes of sleep, cognitive, and functional performance, in acute, hospitalized delirious older adults.

Methods
=======

Subjects
--------

We recruited 228 delirious patients who had been admitted to the GMU, Department of Geriatric Medicine, Tan Tock Seng Hospital, Singapore between December 2010 to August 2012. The subjects were classified into a hyperactive, hypoactive, and mixed delirium subtype, based on their activity patterns. A patient was deemed to have recovered from delirium if the Confusion Assessment Method (CAM)[@b33-cia-8-565] criteria were no longer met, with the diagnosis of recovery being supported by improvement in cognitive and/or delirium severity scores, based on the Delirium Rating Score--R98 (DRS-R98) [@b34-cia-8-565] and CAM-severity scores as well as input from the multidisciplinary team.

Inclusion/exclusion
-------------------

The admission criteria for the GMU included patients above 65 years old who were admitted to the geriatric medicine department and assessed to have delirium (either on admission or incident delirium during hospital stay), established in accordance with the CAM. Patients were excluded if they had medical illnesses that required special monitoring (eg, telemetry for arrhythmias or acute myocardial infarction); were assessed to be dangerously ill, in a coma, or had a terminal illness; uncommunicative or diagnosed with severe aphasia; demonstrated severely combative behavior with high risk of harm; or had contraindications to bright light therapy (manic disorders, severe eye disorders, photosensitive skin disorders, or use of photosensitizing medications). Patients with respiratory or contact precautions, and those with verbal refusal of GMU admission by family/patient/attending physician were also excluded. Patients who were prematurely transferred out of the GMU (for reasons such as instability of medical conditions requiring intensive monitoring, or new requirement of contact precautions) were excluded from subsequent analysis.

Ethics approval for the study was obtained from a National Healthcare Group domain specific review board (DSRB).

Procedure
---------

The GMU consisted of a five-bed unit with a specific elder-friendly room design and lower staff-patient ratios. In addition, core interventions adopted from the HELP program (standardized protocols for managing cognitive impairment, sleep deprivation, immobility, visual impairment, hearing impairment, and dehydration) were systematically administered. Bright light therapy (2000--3000 lux) was administered via lights installed in the ceiling and turned on from 6--10 pm daily. Sleep hygiene principles were also practiced during patients' GMU stay. All interventions were delivered in accordance with a semistructured protocol, by trained geriatric nurses in GMU, with full (100%) compliance achieved.

We collected data on patient demographics (age, gender, race, length of hospital stay \[LOS\]), duration of delirium \[in days\], the medical comorbidities and severity of illness (using a modified Charlson Comorbidity Index[@b35-cia-8-565] and modified Severity of Illness Index),[@b36-cia-8-565] and the precipitating causes of delirium. Cognitive status was assessed using a locally validated Chinese Mini--Mental State Examination (CMMSE)[@b37-cia-8-565] and functional status using a modified Barthel Index (MBI),[@b38-cia-8-565] both administered by a trained assessor during the initial and predischarge phases of the patient admission. The rate and frequency of chemical restraint use was reviewed. As the GMU was a mechanical restraint--free unit, none of the patients in the GMU were subject to physical restraint. To adjust for the different antipsychotics prescribed, we used chlorpromazine equivalence[@b39-cia-8-565] to assess the total antipsychotic usage during the admission and also charted the frequency of benzodiazepine use.

Cognitive assessment
--------------------

All patients underwent a detailed cognitive evaluation by the consultant geriatrician (specializing in cognitive and memory disorders) upon admission to the GMU. A family member or other designated caregiver was routinely interviewed to establish the patient's baseline cognitive functioning prior to the current admission. The medical records of all patients were reviewed to ascertain whether a diagnosis of dementia had been previously established. In patients yet to be diagnosed, a diagnosis of dementia was made in the current admission if the corroborative history suggested presence of cognitive symptoms consistent with DSM-IV criteria for dementia[@b40-cia-8-565] of at least 6-months duration, in accordance with the standardized process for cognitive evaluation.[@b41-cia-8-565]

Sleep data collection
---------------------

Eight specially-trained GMU nurses completed hourly patient sleep logs during the subjects' stay in the GMU, as part of routine clinical care. The total sleep time (TST), number of awakenings, number of sleep bouts (SB), and the length of each SB was computed from the 24-hour sleep log data on admission and discharge from the GMU.

Statistical analysis
--------------------

We evaluated the clinical characteristics, cognitive assessment scores, functional status, and the use of pharmacological agents for the entire cohort of GMU patients and compared among delirium subtypes, using analysis of variance (ANOVA) with Bonferroni correction and Chi-square tests for the continuous and categorical variables, respectively. Sleep parameters for the whole group and delirium subtypes were computed and the differences in the sleep data on discharge and admission were compared using paired-sample *t*-tests. We additionally analyzed the sleep parameters, adjusted for comorbidities, delirium days, and chemical restraint use. Statistical significance was taken to be *P* \< 0.05.

Statistical analyses were performed using SPSS 16.0 software (SPSS, Inc, Chicago, IL, USA).

Results
=======

Demographics
------------

A total of 228 patients were included in the analyses. We excluded 16 subjects who failed screening criteria, 26 subjects whose family members declined GMU admission, and 31 subjects who were prematurely transferred out of GMU due to their medical condition. There were no age, gender, or ethnic differences between the study group and those excluded from the analyses. The majority of patients had hyperactive delirium (n = 117), followed by mixed delirium (n = 69) and hypoactive delirium (n = 42). The mean age was 84.2 ± 7.4 years, and participants were predominantly female (56.4%) and of Chinese ethnicity (88.2%). There were no significant age, gender, or racial differences between the delirium subtypes ([Table 1](#t1-cia-8-565){ref-type="table"}).

Patients with the hyperactive delirium subtype had significantly fewer comorbidities compared with those with hypoactive and mixed delirium (mean Charlson Comorbidity Index score 1.9, 2.9, and 2.5, respectively). Those with hyperactive delirium also had a significantly shorter mean duration of delirium (5.8 ± 3.1 days) compared with those with hypoactive and mixed delirium (7.3 ± 6.0 and 7.9 ± 5.6 days respectively). However, there were no significant differences in LOS across the delirium subtypes.

There were no significant differences in the prevalence of background dementia or number of precipitating causes of delirium. Sepsis was the predominant precipitating cause of delirium (64%--73.9%) among the delirium subtypes.

CMMSE
-----

Although there were significant differences in CMMSE scores among the delirium subtypes on admission and discharge, there was no significant difference in the extent of improvement on the CMMSE nor in any of the delirium indicators among the delirium subtypes upon further analyses.

Functional status
-----------------

There was significant improvement in functional status (MBI) at discharge, especially in the hyperactive and mixed delirium subtype (19.6 ± 18.6 and 19.0 ± 18.4 for the hyperactive and mixed delirium subtypes, respectively, compared with 14.0 ± 2.5 for the hypoactive delirium subtype) (*P* \< 0.05).

Restraint and medication use
----------------------------

None of the subjects were physically restrained. There was decremental chemical restraint use across the hyperactive, mixed, and hypoactive delirium subtypes (47.9%, 43.5%, and 9.5%, respectively) (*P* \< 0.001). However, benzodiazepine use exhibited a different decremental trend across the mixed, hyperactive, and hypoactive delirium subtypes (30.4%, 26.5%, and 9.5% respectively) (*P* = 0.23). (see [Table 1](#t1-cia-8-565){ref-type="table"}).

Sleep
-----

All delirium subtypes showed significant improvement in the DRS sleep--wake disturbance subscore at discharge ([Table 1](#t1-cia-8-565){ref-type="table"}). The GMU cohort also exhibited significant improvement in sleep parameters at discharge from the GMU compared with baseline, with increased TST (7.7 ± 2.5 hours versus 7.1 ± 2.9 hours) (*P* \< 0.01), increased length of first SB (5.9 ± 3.6 hours versus 5.3 ± 3.7 hours) (*P* \< 0.01), decreased number of SB (1.57 ± 0.8 versus 1.59 ± 0.9) (*P* \< 0.01), and fewer number of awakenings (0.6 ± 0.8 versus 0.7 ± 0.8) (*P* = 0.03) (see [Figure 1](#f1-cia-8-565){ref-type="fig"}). In the subgroup analyses of delirium subtypes, there was a significant increase in TST (7.4 ± 2.4 hours versus 6.7 ± 2.8 hours) (*P* \< 0.01) and decreases in number of SB (1.6 ± 0.8 versus 1.7 ± 0.9) (*P* \< 0.01) and length of first SB (5.7 ± 3.4 versus 4.9 ± 3.5) (*P* = 0.002) for hyperactive delirium subtype. For hypoactive delirium, there was a small but significant increase in TST (7.8 ± 3.1 hours versus 7.7 ± 2.7 hours) (*P* = 0.05) (see [Table 2](#t2-cia-8-565){ref-type="table"}). However, upon adjustment for comorbidity, duration of delirium, and chemical restraint use, the differences were no longer statistically significant for any of the sleep parameters except length of SB in hypoactive delirium ([Table 2](#t2-cia-8-565){ref-type="table"}).

Discussion
==========

Our study contributes to the presently still limited literature on sleep outcomes following interventions in delirious older hospitalized adults, with demonstrated improvements in sleep and functional outcomes using bright light therapy as part of a multicomponent intervention program provided in the GMU.

We found significant improvements, with longer TST at night, increased length of the first SB, and decreased number of SBs and thus fewer awakenings in delirious older hospitalized adults admitted to the GMU. The sleep--wake disturbance measured on DRS-subscores also improved, indicating likely consolidation of sleep rhythms. This may be attributed to the increased physical activity, mental stimulation via reorientation, and structured activity programs in the day, along with evening bright light therapy as well as adherence to sleep hygiene principles during the GMU stay.

Of important clinical relevance were the short-term functional improvements, evident in the improvements achieved on MBI for all delirious subtypes, especially in the hyperactive delirium and mixed delirium subtypes. This will promote the geriatric management principles of early intervention and mobilization, and avoidance of physical restraint use, to prevent the complications of hospitalization and immobility.[@b42-cia-8-565] The mean LOS of 15.1 ± 9.3 days in the acute hospital setting compares favorably with the 20.9 ± 2.1 days observed for delirious hospitalized older adults prior to the establishment of the GMU (point prevalence survey). The LOS was longer compared with that of US hospitals due to the funding, subvention structure, and models of geriatric care.

Interestingly, we noted phenomenological differences in delirious patients, where background dementia and behavioral issues prior to admission were more common in hyperactive and mixed delirium. This also related to the nonsignificant differences noted in sedative-hypnotic usage during the delirium episode. This interesting phenomenon is yet to be fully understood in delirium, although Cunningham and MacLullich[@b43-cia-8-565] suggested delirium could be a maladaptive sickness behavioral response, with psychoneuroimmunological changes occurring with a systemic inflammation (for example infection) to manifest severe deleterious effects on brain function (during old age or in the presence of neurodegenerative disease). It was not unexpected that cognitive scores and DRS rating remained impaired despite a clinical impression of delirium resolution and adequate treatment of acute precipitating factors, thus supporting the concept of subsyndromal delirium,[@b44-cia-8-565] even in the resolution stage, and the findings of longer-term cognitive impairment following a delirium episode.

There were some limitations to this study. Since all patients were given the treatment protocol, there was no control group. These results need to be replicated in a randomized controlled study. Sleep parameters were collected via nurse observations through 24-hour sleep logs, with no objective data collected. However, this was a specialized unit with trained GMU nurses completing the sleep logs thus decreasing the risk of observer bias. We were not able to examine circadian activity rhythm changes without the use of wrist actigraphy and therefore could not ascertain whether this multicomponent program would restore rhythms in the delirious hospitalized elderly. Lastly, given that the interventions were performed on all the patients, with 100% compliance, we are not able to accurately delineate the benefits of the individual components of this multicomponent intervention program.

In summary, we have demonstrated improvements in short-term outcomes related to improved function and sleep in delirious hospitalized older adults, in a real-life geriatric setting with bright light therapy as part of a multicomponent delirium program. Longitudinal follow up of cognitive and sleep outcomes and further studies of pharmacologic agents that may help restore sleep and circadian rhythms in delirious hospitalized older adults and the delirium subtypes would facilitate further understanding of this complex phenomenon.
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###### 

Clinical characteristics, cognitive and functional outcomes in GMU patients (n = 228) at baseline

                                                       Total (n = 228)                                           Hyperactive (n = 117)                                     Hypoactive (n = 42)                                      Mixed (n = 69)
  ---------------------------------------------------- --------------------------------------------------------- --------------------------------------------------------- -------------------------------------------------------- ------------------------------------------------------------------------------------------------
  **Demographics**                                                                                                                                                                                                                  
  Age (mean ± SD)                                      84.2 (7.4)                                                83.6 (7.5)                                                84.9 (7.8)                                               84.7 (6.9)
  Gender (male %)                                      43.4                                                      42.7                                                      47.6                                                     42.0
  Race (Chinese %)                                     88.2                                                      93.2                                                      80.9                                                     84.1
  **Comorbidities**                                                                                                                                                                                                                 
  Charlson Comorbidity Index score[@b35-cia-8-565]     2.3 (1.6)                                                 1.9 (1.3)[+](#tfn4-cia-8-565){ref-type="table-fn"}        2.9 (2.20)                                               2.5 (1.6)[\*](#tfn2-cia-8-565){ref-type="table-fn"}
  Severity of Illness Index score[@b36-cia-8-565]      2.0 (0.3)                                                 2.1 (0.2)                                                 2.0 (0.3)                                                2.0 (0.4)
  Days of delirium                                     6.7 (4.6)                                                 5.8 (3.1)                                                 7.3 (6.0)                                                7.9 (5.6)[\*](#tfn2-cia-8-565){ref-type="table-fn"},[\#](#tfn6-cia-8-565){ref-type="table-fn"}
  Length of stay                                       15.1 (9.3)                                                13.9 (7.1)                                                15.0 (10.4)                                              16.6 (11.4)
  **Precipitating causes of delirium**                                                                                                                                                                                              
  Number of precipitating causes, n (%)                                                                                                                                                                                             
   Single precipitating cause                          67 (29.4%)                                                34 (29.1%)                                                9 (21.4%)                                                24 (34.8%)
   Two precipitating causes                            72 (31.6%)                                                38 (32.5%)                                                13 (31.0%)                                               21 (30.4%)
   More than two precipitating causes                  89 (39.0%)                                                45 (38.5%)                                                20 (47.6%)                                               24 (34.8%)
  Type of precipitating cause, n (%)                                                                                                                                                                                                
   Sepsis                                              155 (68.0%)                                               75 (64.1%)                                                29 (69.0%)                                               51 (73.9%)
   Other medical cause                                 48 (21.1%)                                                28 (23.9%)                                                8 (19.0%)                                                12 (17.4%)
   Postoperative                                       7 (3.1%)                                                  4 (3.4%)                                                  1 (2.4%)                                                 2 (2.9%)
   Other surgical cause                                18 (7.9%)                                                 10 (8.5%)                                                 4 (9.5%)                                                 4 (5.8%)
  **Cognitive status**                                                                                                                                                                                                              
  Prior dementia diagnosis (%)                         46.1                                                      44.4                                                      45.2                                                     49.3
  Newly diagnosed dementia during admission (%)        30.3                                                      33.3                                                      33.3                                                     23.1
  Prior behavioral issues before admission (%)         25.1                                                      27.4                                                      9.8                                                      30.4[\*](#tfn2-cia-8-565){ref-type="table-fn"}
  Initial CMMSE[@b37-cia-8-565] (/28)                  5.8 (5.5)                                                 6.9 (5.9)[+](#tfn4-cia-8-565){ref-type="table-fn"}        4.3 (5.3)                                                4.9 (4.4)[\*](#tfn2-cia-8-565){ref-type="table-fn"}
  Last CMMSE (/28)                                     9.2 (6.6)                                                 10.5 (6.4)                                                7.8 (7.2)[++](#tfn5-cia-8-565){ref-type="table-fn"}      7.9 (6.0)[\*](#tfn2-cia-8-565){ref-type="table-fn"}
  Change in CMMSE (/28)                                3.4 (5.5)                                                 3.6 (5.2)                                                 3.5 (6.6)                                                3.0 (5.3)
  Initial CAM[@b33-cia-8-565]                          5.1 (2.0)                                                 5.2 (2.5)                                                 5.3 (1.2)                                                5.0 (1.2)
  Last CAM                                             2.2 (1.2)                                                 1.9 (0.9)                                                 2.3 (1.3)                                                2.5 (1.4)
  Change in CAM                                        −2.9 (2.3)                                                −3.2 (2.7)                                                −3.0 (1.4)                                               −2.4 (1.8)
  Initial DRS severity[@b34-cia-8-565] (/39)           22.5 (5.8)                                                21.6 (6.3)                                                23.1 (5.6)                                               23.6 (4.7)
  Last DRS severity (/39)                              14.6 (6.1)                                                13.5 (95.5)                                               16.0 (7.0)                                               15.4 (6.3)[\*](#tfn2-cia-8-565){ref-type="table-fn"}
  Change in DRS severity (/39)                         −6.2 (6.3)                                                −6.4 (5.8)                                                −5.3 (6.2)                                               −6.2 (7.1)
  Initial DRS total (/46)                              26.2 (6.1)                                                25.3 (6.5)                                                26.9 (5.7)                                               27.3 (5.4)
  Last DRS total (/46)                                 16.3 (6.7)                                                15.2 (5.9)                                                17.8 (7.7)                                               17.2 (7.2)
  Change in DRS total (/46)                            −11.6 (6.1)                                               −11.7 (5.9)                                               −10.9 (5.7)                                              −11.8 (6.9)
  Initial DRS subitem sleep--wake disturbance (/3)     1.9 (0.8)                                                 1.8 (0.8)                                                 1.9 (0.9)                                                1.9 (0.6)
  Last DRS subitem sleep--wake disturbance (/3)        0.7 (0.8)                                                 0.7 (0.8)                                                 0.6 (0.7)                                                0.6 (0.9)
  Change in DRS subitem sleep--wake disturbance (/3)   −1.2 (1.1)[\*\*](#tfn3-cia-8-565){ref-type="table-fn"}    −1.1 (1.1)[\*\*](#tfn3-cia-8-565){ref-type="table-fn"}    −1.3 (0.9)[\*\*](#tfn3-cia-8-565){ref-type="table-fn"}   −1.4 (1.3)[\*\*](#tfn3-cia-8-565){ref-type="table-fn"}
  **Functional scores**                                                                                                                                                                                                             
  MBI[@b38-cia-8-565] admission (/100)                 29.1 (24.1)                                               36.8 (25.9)                                               16.9 (18.7)                                              23.4 (19.2)[\*](#tfn2-cia-8-565){ref-type="table-fn"}
  MBI discharge (/100)                                 47.4 (26.1)                                               56.4 (22.5)                                               30.9 (26.3)                                              42.3 (25.7)[\*](#tfn2-cia-8-565){ref-type="table-fn"}
  Improvement in MBI scores                            18.4 (18.1)[\*\*](#tfn3-cia-8-565){ref-type="table-fn"}   19.6 (18.6)[\*\*](#tfn3-cia-8-565){ref-type="table-fn"}   14.0 (2.5)[\*\*](#tfn3-cia-8-565){ref-type="table-fn"}   19.0 (18.4)[\*\*](#tfn3-cia-8-565){ref-type="table-fn"}
  **Pharmacological agent use**                                                                                                                                                                                                     
  Chemical restraints (%)                              39.5                                                      47.9                                                      9.5                                                      43.5[\*](#tfn2-cia-8-565){ref-type="table-fn"}
  Total antipsychotic use (CPZ equivalent)             0.9 (1.6)                                                 1.2 (1.6)                                                 0 (0)                                                    1.0 (1.7)
  Benzodiazepine usage (%)                             24.6                                                      26.5                                                      9.5                                                      30.4

**Notes:**

ANOVA *P* \< 0.05 across delirium subtypes;

paired sample *t*-test *P* \< 0.05 for GMU cohort and specific delirium subtypes;

post hoc results (with Bonferroni correction) between hyperactive delirium and hypoactive delirium (*P* \< 0.05);

post hoc results (with Bonferroni correction) between hypoactive delirium and mixed delirium (*P* \< 0.05);

post hoc results (with Bonferroni correction) between hyperactive delirium and mixed delirium (*P* \< 0.05).

**Abbreviations:** ANOVA, analysis of variance; CAM, Confusion Assessment Method; CMMSE, Chinese Mini−Mental State Examination; CPZ, chlorpromazine; DRS, Delirium Rating Scale; GMU, Geriatric Monitoring Unit; MBI, modified Barthel Index; SD, standard deviation.

###### 

Sleep parameters for delirium subtypes of GMU patients

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                         Hyperactive (n = 117)                                   Hypoactive (n = 42)                                   Mixed (n = 69)   *P-*value (for change across delirium subtype)   Adjusted *P*-value[\^](#tfn10-cia-8-565){ref-type="table-fn"} (for change across delirium subtype)   Adjusted difference (*P*-value)[\^](#tfn10-cia-8-565){ref-type="table-fn"}\   Adjusted difference (*P*-value)[\^](#tfn10-cia-8-565){ref-type="table-fn"}\   Adjusted difference (*P*-value)[\^](#tfn10-cia-8-565){ref-type="table-fn"}\
                                                                                                                                                                                                                                                                                                                              Hyperactive                                                                   Hypoactive                                                                    Mixed
  -------------------------------------- ------------------------------------------------------- ----------------------------------------------------- ---------------- ------------------------------------------------ ---------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------- ----------------------------------------------------------------------------- -----------------------------------------------------------------------------
  Initial total sleep time (hr)          6.7 (2.8)                                               7.7 (2.7)                                             7.5 (3.0)        --                                               --                                                                                                   --                                                                            --                                                                            --

  Last total sleep time (hr)             7.4 (2.4)                                               7.8 (3.1)                                             8.1 (2.1)        --                                               --                                                                                                   --                                                                            --                                                                            --

  Change in total sleep time (hr)        0.7 (3.0)[\#](#tfn9-cia-8-565){ref-type="table-fn"}     0.1 (3.5)[\#](#tfn9-cia-8-565){ref-type="table-fn"}   0.7 (3.3)        0.61                                             0.51                                                                                                 0.20                                                                          0.26                                                                          0.28

  Initial number of awakenings           0.8 (0.8)                                               0.6 (0.8)                                             0.7 (0.8)        --                                               --                                                                                                   --                                                                            --                                                                            --

  Last number of awakenings              0.7 (0.8)                                               0.3 (0.5)                                             0.6 (0.8)        --                                               --                                                                                                   --                                                                            --                                                                            --

  Change in number of awakenings         −0.1 (1.1)                                              −0.2 (0.8)                                            −0.1 (1.0)       0.55                                             0.93                                                                                                 0.82                                                                          0.11                                                                          0.67

  Initial number of sleep bouts          1.7 (0.9)                                               1.5 (0.9)                                             1.6 (0.8)        --                                               --                                                                                                   --                                                                            --                                                                            --

  Last number of sleep bouts             1.6 (0.8)                                               1.3 (0.6)                                             1.7 (0.9)        --                                               --                                                                                                   --                                                                            --                                                                            --

  Change in number of sleep bouts        −0.04 (1.1)[\#](#tfn9-cia-8-565){ref-type="table-fn"}   −0.2 (0.9)                                            0.1 (1.1)        0.41                                             0.95                                                                                                 0.82                                                                          0.11                                                                          0.74

  Length of first sleep bout (hr)        4.9 (3.5)                                               5.7 (3.9)                                             5.8 (3.8)        --                                               --                                                                                                   --                                                                            --                                                                            --

  Last length of first sleep bout (hr)   5.7 (3.4)                                               6.6 (3.9)                                             6.0 (3.7)        --                                               --                                                                                                   --                                                                            --                                                                            --

  Change in length of sleep bout (hr)    0.8 (4.2)[\#](#tfn9-cia-8-565){ref-type="table-fn"}     0.9 (4.6)                                             0.2 (4.8)        0.60                                             0.57                                                                                                 0.35                                                                          0.01                                                                          0.38
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:**

Statistically significant differences in change across the sleep parameters (total sleep time, number of awakenings, number of sleep bouts, and length of first sleep bout) for the specific delirium subtype;

differences adjusted for Charlson Comorbidity Index,[@b35-cia-8-565] days of delirium, and use of chemical restraints.

**Abbreviation:** GMU, Geriatric Monitoring Unit.
